Dimensional Fund Advisors’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Dimensional Fund Advisors’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-244,889	Closed	-$18.4M	–	3575
2022 Q2	$18.4M	Buy	244,889 +92,756	+61%	+$4.12M	0.01%	1909
2022 Q1	$4.08M	Buy	152,133 +52,657	+53%	+$1.77M	﹤0.01%	2597
2021 Q4	$4.75M	Buy	99,476 +18,661	+23%	+$834K	﹤0.01%	2577
2021 Q3	$5.37M	Buy	80,815 +31,156	+63%	+$2.22M	﹤0.01%	2562
2021 Q2	$3.87M	Sell	49,659 -45,165	-48%	-$3.34M	﹤0.01%	2680
2021 Q1	$8.99M	Buy	94,824 +70,618	+292%	+$8.4M	﹤0.01%	2369
2020 Q4	$2.95M	Buy	+24,206	New	+$2.65M	﹤0.01%	2697

Dimensional Fund Advisors's TPTX Position: Q3 2022 in Review

Dimensional Fund Advisors sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 244,889 shares — an estimated $18.4M sold.

Dimensional Fund Advisors first reported a position in TPTX in Q4 2020 and held it in 7 quarters. The position peaked at $18.4M in Q2 2022. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

Dimensional Fund Advisors reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Dimensional Fund Advisors sold 244,889 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $18.4M.
Dimensional Fund Advisors first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q4 2020 and held it in 7 quarters.
Dimensional Fund Advisors's Turning Point Therapeutics, Inc. Common Stock position peaked at $18.4M in Q2 2022.
0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Dimensional Fund Advisors's 13F filing for Q3 2022, filed 10 Nov 2022.